Global HbA1c Testing Device Market Growth 2023-2029

Global HbA1c Testing Device Market Growth 2023-2029

HbA1c levels, which reflect the average plasma glucose concentration over the preceding three months, play a pivotal role in the diagnosis, assessment, and monitoring of diabetes.

HbA1c is your average blood glucose (sugar) levels for the last two to three months.

The immediate feedback of HbA1c levels is highly effective for controlling plasma glucose levels and point-of-care (POC) instruments, characterized as fast, and easy-to-use, have been shown to be suitable for providing rapid feedback of HbA1c levels.

LPI (LP Information)' newest research report, the “HbA1c Testing Device Industry Forecast” looks at past sales and reviews total world HbA1c Testing Device sales in 2022, providing a comprehensive analysis by region and market sector of projected HbA1c Testing Device sales for 2023 through 2029. With HbA1c Testing Device sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HbA1c Testing Device industry.

This Insight Report provides a comprehensive analysis of the global HbA1c Testing Device landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HbA1c Testing Device portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global HbA1c Testing Device market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HbA1c Testing Device and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HbA1c Testing Device.

The global HbA1c Testing Device market size is projected to grow from US$ 1566.9 million in 2022 to US$ 3025.3 million in 2029; it is expected to grow at a CAGR of 3025.3 from 2023 to 2029.

North America is the largest region of HbA1c Testing Device, with a market share about 40%. It was followed by Europe with 30%. The industry's leading producers are Abbott Laboratories, Roche and Siemens, and they had about 30% combined market share.

This report presents a comprehensive overview, market shares, and growth opportunities of HbA1c Testing Device market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Bench-top

Compact

Portable

Segmentation by application

Hospital

Homecare

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Abbott Laboratories

Roche

Siemens

Bio-Rad Laboratories

Tosoh

Danaher Corporation

Trinity Biotech

HUMAN Diagnostics

Arkray

OSANG Healthcare

Key Questions Addressed in this Report

What is the 10-year outlook for the global HbA1c Testing Device market?

What factors are driving HbA1c Testing Device market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do HbA1c Testing Device market opportunities vary by end market size?

How does HbA1c Testing Device break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.